Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 9, 2021CancersOpen Access

Current Knowledge about Mechanisms of Drug Resistance against ALK Inhibitors in Non-Small Cell Lung Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

ESElisabeth SmolleMedical University of GrazVTValentin TaucherMedical University of GrazJLJoerg LindenmannUniversity of Graz

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Smolle et al. (2021) studied this question.

synapsesocial.com/papers/6a0ccd76c031bbff4134c40dhttps://doi.org/10.3390/cancers13040699
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Brigatinib versus Crizotinib in <i>ALK</i> -Positive Non–Small-Cell Lung Cancer2018 · 997 citations
  2. 2The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models2016 · 331 citations
  3. 3Targeting anaplastic lymphoma kinase in neuroblastoma2019 · 80 citations